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Summary The polymerase chain reaction has been used to determine the presence of human papillomavirus
(HPV) 16 and HPV 18 DNA sequences in archival histological material removed from a cohort of untreated
women with cervical epithelial abnormalities. The detection of HPV 16 or 18 DNA sequences in the initial
biopsy specimen was associated with a significantly increased risk of subsequent disease progression.
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Over the last 12 years a stream ofimaginative and resourceful
laboratory-based research has established an impressive set of
oncogenic credentials for human papillomavirus (HPV). Two
large population-based case-control studies have provided
further support for its aetiological role in cervical neoplasia
(Reeves et al., 1989; Munoz et al., 1992) and we now await
the outcome of cohort studies in which longitudinal
observations are made on subjects whose exposure status
has been defined before the onset of disease. Such studies are
under way but it will be some time before they are reported.
An alternative strategy is to recruit a cohort of subjects who
are likely to be at greater risk of developing cervical
intraepithelial neoplasm (CIN) III and to determine the risk
of progression in this cohort according to baseline HPV
status. The aim of this study was to describe the association
between the finding of HPV DNA sequences in the initial
biopsies taken from a cohort of untreated patients with
epithelial abnormalities of the cervix and the risk of
subsequent progression of disease.
Patients and methods
A randomised control trial undertaken some years ago
provided a cohort of untreated patients with cervical
epithelial abnormalities. The details of this trial have been
outlined elsewhere (Woodman et al., 1993). In brief, all
women referred to the colposcopy clinics in the Birmingham
and Midlands Hospital for Women between October 1983
and July 1985 for evaluation of cervical abnormality were
included in the trial if: (a) the colposcopist making the first
assessment considered them suitable for out-patient laser
vaporisation and; (b) histological examination of a colposco-
pically directed punch biopsy revealed changes consistent
with cervical human papillomavirus infection either alone or
in association with CIN I or CIN II. Our criteria for selecting
patients for laser vaporisation and the histological features
used to diagnose HPV infection have previously been
described (Byrne et al., 1986).
Eligible patients were randomised into treatment and non-
treatment groups. Untreated patients were monitored by
regular cytological and colposcopic examination at intervals
of 4 months and further histological sampling performed if
the cytological or colposcopic findings suggested progression
of disease. Progression of disease was defined as histological
evidence of a change from HPV infection alone to CIN or an
increase in the grade of CIN.
Laboratory methods
When the randomised controlled trial was undertaken,
routine determination of HPV DNA sequences in histologi-
cal material was not feasible. It is now possible, however,
using the polymerase chain reaction (PCR) to describe the
presence of HPV DNA sequences in archival histological
material (Imprain et al., 1987; Shibata et al., 1988; Resmick
et al., 1990). This allowed an assessment of the risk of
progression in this cohort of untreated patients in relation to
the presence of specific HPV DNA types in the baseline
biopsy material. Unfortunately, the complete cohort of
untreated patients could not be included in this analysis.
Although all patients have been assessed in a dedicated
research clinic by one observer, histological material removed
during the course of the trial had been processed in one of
two laboratories dependent upon the consultant to whom the
patient had been initially referred. One laboratory routinely
fixed specimens in Bouin's fluid and the other in formal
saline. The use of the former fixative has been shown to
inhibit the detection of HPV DNA sequences and these cases
have been discarded. Baseline histological material from the
remaining 93 cases was tested for the presence of HPV 16 or
18 DNA sequences using the PCR.
PCR methodology
Paraffin-embedded tissue sections (5 x 10 jgM) were cut into a
sterile Eppendorf tube and de-waxed using xylene. After
centrifugation the xylene was removed, the tissue washed in
70% ethanol and the resultant pellet air dried. The tissue was
then resuspended in 500 pl of 1 x PCR buffer (10 mM Tris-
HCl, 1.5 mM magnesium-chloride, 50 mM potassium chlor-
ide, 0.1 mg ml-' gelatine, pH 8.3) containing 100 Mg ml-'
proteinase K and 0.5% Tween 80 at 55°C for 60 min, then
incubated at 94°C for 10 min. A 10 Ml aliquot of this
preparation was then amplified in a 100 jl reaction as
previously described (Tierney et al., 1993) using LI
consensus oligonucleotide primers (Bauer et al., 1991). The
PCR consisted of primer extension for 2 min at 70°C,
denaturation for 30 s at 94°C and reannealing for 90 s at
45°C. This was repeated for 40 cycles and the resulting
amplified products were separated on a 3% agarose gel. The
type specificity of the amplified products was assessed by
Southern blotting followed by hybridisation with either an
HPV 16-specific or an HPV 18-specific internal oligonucleo-
tide probe. These probes were end labelled with 32
phosphorus using T4 polynucleotide kinase. The presence of
amplifiable DNA in all extracted cases was confirmed using
primers PCO3 and PCO4 specific for the human B-globin gene
(Saiki et al., 1985).
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Statistical methods
Actuarial curves for the time to progression'
the method of Kaplan and Meier and con
log-rank test (Kaplan and Meier, 1958). T
used when comparing the proportion c
progressive disease at 48 months in the I
HPV-negative groups. Hazard ratios were a
describe the magnitude of the association
status for each level of histological at
confidence intervals were constructed rour
estimates (Machin and Gardner, 1988).
Results
A total of 47 (51%) of the 93 subjects wei
HPV 16 and/or 18 DNA sequences in thei
specimens; 39 had HPV 16 alone; two HPV
both HPV 16 and 18. The remaining 46 (4
not have HPV 16 or 18 DNA sequences
biopsy specimen and are hereafter referi
negative. The mean age of HPV-positive s
years (s.d. 7.7) and HPV-negative subjects
7.5).
Of the 47 HPV-positive subjects, 21
histological diagnosis of HPV infection;
also had CIN I and 14 (30%) CIN II. (
negative subjects, 24 (53%) had a histolog
HPV infection alone, 15 (33%) also had
(15%) CIN II.
Median follow-up for all subjects was 3
4-84 months), 15 subjects (seven HPV-posi
negative) were eventually treated, althoug
evidence of disease progression. These (
censored at the date of treatment. The prob
progression by baseline HPV status is shc
Five HPV-positive subjects progressed to C]
II and 18 to CIN III. Two HPV-negative su
to CIN I, four to CIN II and seven to CIl
following randomisation, the proportion
subjects progressing to more severe di
compared with 25% of the HPV-negativ
confidence on difference in proportions 10-
progression in the HPV-positive group co
negative group, expressed as an odds rati
(95% CI 1.23, 4.27) for all cases, 1.87 (95%
those with histological evidence of HPV infi
(95% CI 0.8, 11.65) for subjects with CIN
CI 0.6, 5.7) for subjects with CIN II. Whe
CIN III was used as the sole study end 1
progression was found to be significantly
positive subjects (P=0.015) (Figure 2).
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Discussion
subjects was 31.3 This study suggests that the presence of HPV 16 or 18 DNA
29.5 years (s.d. sequences in baseline histological material taken from women
with minor epithelial abnormalities of the cervix is associated
I (45%) had a with an increased risk of disease progression. The magnitude
alone, 12 (26%) and direction of this association were similar for each level of
Of the 46 HPV- histological abnormality. The findings are consistent with a
,ical diagnosis of number of previous reports. Campion et al. (1986) described
CIN I and seven a prospective study of 100 women with recurrent mildly
dyskaryotic smears; 58% of those positive for HPV 16
}6 months (range progressed to CIN III within 2 years as compared with 20%
itive and 8 HPV- of those with HPV 6. Koutsky et al. (1992) recruited a cohort
;h there was no of 241 women with negative cytology who were attending a
cases have been sexually transmitted disease clinic; those who were HPV 16 or
)ability of disease 18 positive were significantly more likely to progress to CIN
nwn in Figure 1. II/III (OR= 11, 95% confidence intervals 4.6, 26). Murthy et
IN I, five to CIN al. (1990) using a nested case control design within a large
ibjects progressed cohort study again confirmed a significant risk of progression
.I III. Four years associated with the presence of baseline HPV 16 or 18 DNA
of HPV-positive sequences (OR=5.9, 95% confidence intervals 2.5-14.1).
vsease was 56% All studies of the natural history of early cervical
re subjects (95% neoplasia share a number of methodological problems. The
48%). The risk of first relates to the possible misclassification of baseline disease
mpared with the status. This is more likely when baseline status is defined on
io (OR) was 2.3 the results of cytological examination, which aims for
CI 0.75, 4.08) for detection rather than diagnostic accuracy. Histological
ection alone, 3.05 examination of cervical tissue is more likely to provide an
I and 1.77 (95% accurate diagnosis but this cannot always be guaranteed,
mn progression to because the most abnormal part of the lesion may not have
point the risk of been sampled. It has been suggested that the removal of
greater in HPV- tissue for diagnostic purposes may influence the natural
history of the disease (Barron and Richart, 1968). The
likelihood of this occurring is, of course, dependent upon the
volume of tissue removed. Before the introduction of
colposcopy and the use of local destructive techniques large
wedge biopsies were removed from the cervix for diagnostic
purposes. These may have been sufficient in some circum-
stances to abort the disease process. It is an entirely different
proposition to suggest that the small volume of tissue
removed by a colposcopically directed punch biopsy is
sufficient to ensure disease regression in a substantial
number of cases. The investigator is nevertheless obliged to
trade off the need for an accurate definition of baseline status
against the possibility that the means necessary to achieve
48 60 this may influence the disease process. The next problem relates to the detection of disease
progression. CIN is an asymptomatic condition and therefore
progression cannot be measured in continuous time. It can
6 only be suspected by periodic observations made at discrete
intervals using cytological and colposcopic examination, and
2 only confirmed or refuted by histological examination. There
is inevitably an element of subjectivity in deciding when the
baseline HPV 16 results of cytological and colposcopic examinations merit
further histological sampling.
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The same techniques must be used to establish follow-up
and baseline disease status. It is not, for example, acceptable
to define baseline disease status on the results of
colposcopically directed punch biopsy and outcome on the
results of a loop biopsy or cone biopsy. The use of the latter
techniques allow for the removal of substantially greater
volumes of tissue that provide for a more precise
topographical description of the severity of the lesion.
There is a further difficulty in deciding what change in
disease severity constitutes evidence of disease progression.
Intuitively, the discovery of a CIN III lesion in a patient
found to have CIN I at baseline provides more persuasive
evidence of progression than when a CIN II lesion is
discovered after the initial diagnosis of CIN I. Alterna-
tively, both examples could be construed as evidence of
progression from a 'low-grade' (HPV/CIN I) to a 'high-
grade' lesion (CIN II/III). It might also be argued that
changes in disease status over a short period of time are more
likely to reflect misclassification following sampling error
rather than true progression. Unfortunately, this requires us
to make prior assumptions about the tempo of disease
progression. These difficulties would be reduced, but not
abolished, if CIN III alone was used as the study end point.
When this study was initiated ethical considerations
dictated that women be treated at the time of histological
confirmation of any disease progression. This was almost
certainly unnecessary, as some cases might still have
undergone spontaneous regression of epithelial abnormality.
Nevertheless, sufficient women in this series have progressed
to CIN III without any detectable intermediate stage to
reveal a significant association between baseline HPV status
and progression to CIN III.
All of the above caveats relating to the definition of
baseline disease status also apply to the definition of baseline
virological status, which will be influenced by the detection
system used, the material provided for analysis and the
accuracy of the sampling technique.
In this study we have only considered the prognostic
importance of finding HPV 16 and 18 DNA sequences. We
did not test for the presence of HPV 6/11 sequences because
there was no a priori reason to believe these types were
associated with an increased risk of disease progression. A
high prevalence ofother 'high-risk' HPV types (31, 33, 35, 39,
45, 51 or 52) have been reported in some North American
series but surprisingly infrequently in this country (Cuzick et
al., 1992; Schiffman et al., 1993). This may, of course, merely
reflect the assiduousness with which they have been sought. If
we had tested for the presence of other 'high-risk' HPV DNA
types, this might have accentuated the difference between the
progression curves.
Given these uncertainties, how robust are the conclusions
that can be drawn from any analysis of risk factors for
disease progression? It is clear that misclassification of
virological status and disease status at baseline and during
follow-up will have occurred. It is important to decide if this
misclassification is likely to be random or systematic.
Random misclassification will merely reduce differences
between groups and attenuate measures of association.
Systematic misclassification is more serious. If, for example,
prior knowledge of virological status were to influence
baseline or more importantly follow-up disease status, as a
result of more intensive follow-up of HPV-positive patients,
then spurious conclusions might be drawn. However, if
virological status, baseline disease and follow-up status are
independently defined, then these errors are likely to be
random and as such will only underestimate the true risk of
progression associated with HPV status. In this study the
technological developments necessary to determine virological
status only became available some years after the clinical trial
had been completed, and both pathologist and clinician were
therefore blind to the baseline HPV status of the cases.
The next major concern relates to the possibility of
confounding. The association of HPV status with progres-
sion may be confounded if HPV infection is also associated
with another factor that is itself a risk factor for progression.
Risk of disease progression may be associated with baseline
disease status but this study revealed a consistent association
with HPV status for each level of baseline abnormality. Size
of lesion has also been described as a risk factor for disease
progression but there is no evidence linking HPV status and
size. One other study has shown that the risk of disease
progression is associated with the finding of other sexually
transmitted agents including HPV but this analysis confirmed
HPV status as an independent risk factor (Koutsky et al.,
1992).
There is another more serious reservation that applies to
all natural history studies that use CIN III as an end point.
Although the presence of HPV 16/18 infection may accelerate
progression to CIN III, not all cases of CIN III will progress
to invasive cancer (Kiviat et al., 1992). As we cannot yet
distinguish those cases which will progress it might be unwise
to infer from these data that HPV infection results in the
inexorable progression of all CIN lesions to invasive cancer.
Acknowledgement
We would like to acknowledge the conrtinuing support and
collaboration of clinicians in the Birmingham and Midlands
Hospital for Women.
References
BARRON BA AND RICHART RM. (1968). A statistical model of the
natural history ofcervical carcinoma based on aprospective study
of 557 cases. J. Natl Cancer Inst., 6, 1343-1353.
BAUER HM, TING Y, GREER CE, CHAMBERS JC, TASHIRO CJ,
CHIMERA J, REINGOLD A AND MANOS MM. (1991). Genital
human papillomavirus infection in female university students as
determined by a PCR-based method. J. Am. Med. Assoc., 265,
472-477.
BYRNE P, WOODMAN CBJ, MEANWELL CA, KELLY K AND
JORDAN JA. (1986). Koilocytosis and cervical human papilloma-
virus infection. Lancet, 1, 205-206.
CAMPION MJ, McCANCE DJ, CUZICK J AND SINGER A. (1986).
Progressive potential of mild cervical atypia: prospective
cytological, colposcopic, and virological study. Lancet, 2, 237-
240.
CUZICK J, TERRY G, HO L, HOLLINGWORTH T AND ANDERSON
M. (1992). Human papillomavirus type 16 DNA in cervical smears
as predictor ofhigh-grade cervical cancer. Lancet, 339, 959-960.
IMPRAIN CC, SAIKI RK, ERLICH HA AND TEPLITZ RL. (1987).
Analysis of DNA extracted from formalin-fixed, paraffin-
embedded tissues by enzymatic amplification and hybridisation
with sequence-specific oligonucleotides. Biochem. Biophys. Res.
Commun., 142, 710-716.
KAPLAN EL AND MEIER P. (1958). Non-parametric estimation from
incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
KIVIAT NB, CRITCHLOW CW AND KURMAN RJ. (1992). Reassess-
ment of the morphological continuum of cervical intraepithelial
lesions: does it reflect different stages in the progression to cervical
carcinoma? In The Epidemiology of Human Papillomavirus and
Cervical Cancer IARC Scientific Publication. Munoz N, Bosch
FX, Shah K and Meheus. pp. 59-66. IARC: Lyon.HPV infeceion and epithelial abnormalities of the cervix
CBJ Woodman et al
KOUTSKY LA, HOLMES KK, CRITCHLOW SW, STEVENS CE,
PAAVONEN J, BECKMAN AM, DEROUEN TA, GALLOWAY DA,
VERNON D AND KIVIAT NB. (1992). A cohort study ofthe risk of
cervical intraepithelial neoplasia grade 2 or 3 in relation to
papillomavirus infection. New Engl. J. Med., 327, 1272- 1278.
MACHIN D AND GARDNER MJ. (1988). Calculating confidence
intervals for survival time analysis. Br. Med. J., 296, 1369- 1371.
MUNOZ N, BOSCH FX, DE SANJOSE S, TAFUR L, IZARZUGAZA I,
GILI M, VILADIU P, NAVARRO C, MARTOS C, ASCUNCE N,
GONZALEZ LC, KALDOR JM, GUERRERO E, LORINCZ A,
SANTAHARIA M, DE RUIZ PA, ARISTIZABAL N AND SHAH K.
(1992). The causal link between human papillomavirus and
invasive cervical cancer: a population-based case-control study
in Columbia and Spain. Int. J. Cancer, 52, 743-749.
MURTHY NS, SEHGAL A, SATYANARAYANA L, DAS DK, SINGH V,
DAS BC, GUPTA MM, MITRA AB AND LUTHRA UK. (1990). Risk
factors related to biological behaviour ofprecancerous lesions of
the uterine cervix. Br. J. Cancer, 61, 732-736.
REEVES WC, BRINTON LA, GARCIA M, BRENES MM, HERRERO R,
GAITAN E, TENORIO P, DE BRITTON RC AND RAWLS WE.
(1989). Human papillomavirus infection and cervical cancer in
Latin America. New Engl. J. Med., 320, 1437- 1441.
RESNICK RM, CORNELISSEN MT, WRIGHT DK, EICHINGER GH,
FOX HS, TER-SCHEGGET J AND MANOS MM. (1990). Detection
and typing of human papillomavirus in archival cervical cancer
specimens by DNA amplification with consensus primers. J. Natl
Cancer Inst., 82, 1477-1484.
SAIKI RK, SCHARF S, FALOONA F, MULLIS KB, HORN GT, ERLICH
HA AND ARNHEIM N. (1985). Enzymatic amplification of Beta-
globin genomic sequences and restriction site analysis for
diagnosis of sickle cell anemia. Science, 230, 1350-1354.
SCHIFFMAN MH, BAUER HM, HOOVER RN, GLASS AG, CADELL
DM, RUSH BB, SCOTT DR, SHERMAN ME, KURMAN RJ,
WACHOLDER S, STANTON CK AND MANOS MM. (1993).
Epidemiologic evidence showing that human papillomavirus
infection causes most cervical intraepithelial neoplasia. J. Natl
Cancer Inst., 85, 958-964.
SHIBATA DK, ARNHEIM N AND MARTIN WJ. (1988). Detection of
HPV in paraffin-embedded tissue using polymerase chain
reaction. J. Exp. Med., 167, 225-230.
TIERNEY R, ELLIS J, WINTER H, KAURESHI H, WILSON S,
WOODMAN CBJ AND YOUNG LS. (1993). PCR for the detection
of HPV16 infection: the need for standardisation. Int. J. Cancer,
54, 1-2.
WOODMAN CBJ, BYRNE P, KELLY KA AND HILTON C. (1993). A
randomised trial of laser vaporisation in the management of
cervical intraepithelial neoplasia associated with HPV infection.
J. Pub. Health Med., 15, 327-331.